

Geert Maertens

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11898541/geert-maertens-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

4,885
citations

19
h-index

31
g-index

31
ext. papers

5,222
ext. citations

11.5
avg, IF

3.91
L-index

#	Paper	IF	Citations
30	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1397-404	6.1	61
29	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016 , 14, 95	8.5	98
28	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. <i>Melanoma Research</i> , 2016 , 26, 157-63	3.3	14
27	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015 , 6, 26886-94	3.3	38
26	Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. <i>Journal of Infectious Diseases</i> , 2011 , 204, 837-44	7	33
25	Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. <i>Liver International</i> , 2008 , 28, 807-13	7.9	10
24	Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. <i>Hepatology</i> , 2005 , 42, 962-73	11.2	1136
23	Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. <i>Journal of Virology</i> , 2004 , 78, 9030-40	6.6	63
22	A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. <i>Vaccine</i> , 2004 , 22, 3080-6	4.1	58
21	A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. <i>Hepatology</i> , 2003 , 38, 1289-96	11.2	101
20	Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. <i>Journal of General Virology</i> , 2002 , 83, 1673-1678	4.9	8
19	Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers 2000 , 60, 126-132		16
18	Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. <i>Nature Medicine</i> , 2000 , 6, 578-82	50.5	612
17	HCV Genotyping by the Line Probe Assay INNO-LiPA HCV II. <i>Methods in Molecular Medicine</i> , 1999 , 19, 183-98		2
16	Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. <i>Transplantation</i> , 1999 , 67, 78-84	1.8	17
15	Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. <i>Journal of Medical Virology</i> , 1998 , 55, 92-97	19.7	105
14	HCV genotypes in patients with liver disease of different stages and severity. <i>Journal of Hepatology</i> , 1997 , 26, 1173-8	13.4	42

13	Serological and molecular analysis of hepatitis C virus envelope regions 1 and 2 during acute and chronic infections in chimpanzees. <i>Journal of Medical Virology</i> , 1997 , 52, 441-50	19.7	10
12	Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. <i>Kidney International</i> , 1996 , 49, 889-95	9.9	72
11	Long-term outcome of hepatitis C infection after liver transplantation. <i>New England Journal of Medicine</i> , 1996 , 334, 815-20	59.2	864
10	Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. <i>Gastroenterology</i> , 1995 , 108, 1088-96	13.3	244
9	Hepatitis C virus genotyping by means of 5UR/core line probe assays and molecular analysis of untypeable samples. <i>Virus Research</i> , 1995 , 38, 137-57	6.4	123
8	Rapid detection of hepatitis C virus RNA by direct capture from blood. <i>Journal of Medical Virology</i> , 1994 , 42, 22-8	19.7	19
7	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994 , 19, 1321-1324	11.2	854
6	Genotypic analysis of hepatitis C virus in American patients. <i>Hepatology</i> , 1994 , 20, 1405-11	11.2	163
5	Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles. <i>Journal of Hepatology</i> , 1994 , 21, 122-9	13.4	46
4	Low Prevalence of Anti-E1 Antibodies Reactive to Recombinant Type 1b E1 Envelope Protein in Type 2, 3, and 4 HCV Sera, but High Prevalence in Subtypes 1a and 1b 1994 , 314-316		1
3	Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. <i>Vaccine</i> , 1993 , 11, 1185-7	4.1	14
2	Hepatitis C virus antibody detection by a line immunoassay and (near) full length genomic RNA detection by a new RNA-capture polymerase chain reaction. <i>Journal of Medical Virology</i> , 1992 , 38, 298-304	19.7	10
1	High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors. <i>Gene</i> , 1988 , 66, 163-81	3.8	51